Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 6/20 | 0.61 |
| ▸ | PPARG | P37231 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 2/20 | 0.47 |
| ▸ | CISD1 | Q9NZ45 | 2/20 | 0.47 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6202350 | 0.89 | FFAR1 (0.73) | FFAR1PPARGALDH1A1NPSR1MAOA | |
| SCHEMBL6183947 | 0.88 | FFAR1 (0.58) | FFAR1PPARGALDH1A1NPSR1MAOA | |
| SCHEMBL6187556 | 0.85 | FFAR1 (0.60) | FFAR1PPARGMAOBMAPTPPARA | |
| Phenylacetic Acid SCHEMBL6188575 | 0.84 | FFAR1 (0.65) | FFAR1PPARGALDH1A1NPSR1MAOA | |
| SCHEMBL6184770 | 0.84 | FFAR1 (0.59) | FFAR1PPARGMAPTPPARA | |
| SCHEMBL6183773 | 0.82 | FFAR1 (0.56) | FFAR1PPARGCA2 | |
| SCHEMBL6184667 | 0.81 | FFAR1 (0.59) | FFAR1PPARGALDH1A1NPSR1MAPT | |
| SCHEMBL5395861 | 0.81 | FFAR1 (0.63) | FFAR1PPARGALDH1A1NPSR1MAOA | |
| SCHEMBL6184691 | 0.80 | FFAR1 (0.54) | FFAR1PPARGALDH1A1NPSR1MAOA | |
| SCHEMBL5399583 | 0.79 | FFAR1 (0.61) | FFAR1PPARGALDH1A1NPSR1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | claimed |
| EP-1309575-B1 | BIPHENYL DERIVATIVES AND THEIR USE AS PPAR-GAMMA RECEPTOR ACTIVATORS | GALDERMA RES & DEV (FR) | 2005-06-08 | — | — | EP | claimed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | claimed |
| US-6927228-B2 | Biphenyl compounds usefuf in treatment of human and veterinary medicines such as dermatology, cardivovascular diseases, immune diseases or diseases associated with lipid metabolisms, or in cosmetic formulation | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-08-09 | — | — | US | disclosed |
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | GALDERMA RESEARCH & DEVELOPMENT S.N.C. (FR) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039038-A1 | Biaromatic compound activators of PPARy-type receptors | PPARG, PPARA, PPARD | FFAR1 6/4885PPARG 1/4885ALDH1A1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.